Supply continues to cause headaches for radiopharmaceutical developers.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.

The group is keeping faith with the novel target KLK2.

Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.

But toxicity could hold back Destiny-Breast06's ability to change clinical practice.